Marshall Wace, LLP Crispr Therapeutics Ag Transaction History

Marshall Wace, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $9.55 Million - $12.7 Million	186,591 New	186,591 $10.1 Million
Q4 2023 Feb 14, 2024	SELL	$38.62 - $72.18 $5.13 Million - $9.58 Million	-132,747 Reduced 97.65%	3,200 $200,000
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $14.6 Million - $18.9 Million	-321,061 Reduced 70.25%	135,947 $6.17 Million
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $19.9 Million - $31 Million	457,008 New	457,008 $25.7 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $665,562 - $912,615	10,893 New	10,893 $712,000
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $17.9 Million - $28.5 Million	-255,727 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $28.2 Million - $40.1 Million	255,727 New	255,727 $28.6 Million
Q2 2020 Aug 13, 2020	SELL	$38.5 - $76.05 $73,804 - $145,787	-1,917 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$33.68 - $62.53 $15,391 - $28,576	-457 Reduced 19.25%	1,917 $81,000
Q4 2019 Feb 14, 2020	BUY	$36.68 - $73.13 $87,078 - $173,610	2,374 New	2,374 $145,000
Q2 2018 Aug 14, 2018	SELL	$42.62 - $73.59 $197,202 - $340,500	-4,627 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $108,827 - $269,152	4,627 New	4,627 $212,000

489

57.9M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.16B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.